Kayexalate and Alcohol/Food Interactions
There are 3 alcohol/food/lifestyle interactions with Kayexalate (sodium polystyrene sulfonate).
Sodium Polystyrene Sulfonate Multivitamins With Minerals
Moderate Drug Interaction
ADJUST DOSING INTERVAL: Simultaneous administration of cation-donating preparations may reduce the potassium exchange capability of cation-exchange resins due to binding of the cation to the resin.
MANAGEMENT: Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.g., mineral supplements; antacids; products containing antacids such as didanosine buffered tablets or pediatric oral solution) by several hours if possible.
References (2)
- (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
- (2002) "Product Information. Resonium Calcium (calcium polystyrene sulfonate)." Sanofi-Synthelabo Canada Inc
Sodium Polystyrene Sulfonate Food
Moderate Food Interaction
GENERALLY AVOID: Potassium in foods can bind to the cation exchange resin and interfere with potassium removal in the treatment of hyperkalemia.
MANAGEMENT: Cation exchange resins should not be mixed with orange juice or other foods with a high potassium content.
ADJUST DOSING INTERVAL: Cation exchange resins may bind to other medications that are administered orally. Reduced systemic absorption and therapeutic efficacy may occur. Manufacturers have reported that polystyrene sulfonate exchange resins can decrease the absorption of lithium and levothyroxine. A more recent study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medications. Another potassium-lowering drug, patiromer, has also been found to bind about half of the medications tested, some of which are commonly used in patients who require potassium-lowering drugs.
MANAGEMENT: To minimize the risk of interaction, patients should be advised to separate the dosing of the cation exchange resin from other orally administered medications by at least 3 hours. The dosing interval should be increased to 6 hours for patients with gastroparesis or other conditions resulting in delayed emptying of food from the stomach into the small intestine. Health care professionals should monitor blood levels and/or clinical response to the other medications when appropriate.
References (3)
- (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Switch to consumer interaction data
Sodium Polystyrene Sulfonate High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
sodium polystyrene sulfonate - sodium load
The use of sodium polystyrene sulfonate is associated with an elevation in sodium. Therapy with sodium polystyrene sulfonate should be administered cautiously in patients with conditions that might be exacerbated by additional sodium such as severe congestive heart failure, severe hypertension, or marked edema. Compensatory restriction of sodium intake from other sources may be indicated.
References (2)
- (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
- Meyer I (1993) "Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia." ANNA J, 20, p. 93-5
Switch to consumer interaction data
Kayexalate drug interactions
There are 128 drug interactions with Kayexalate (sodium polystyrene sulfonate).
Kayexalate disease interactions
There are 3 disease interactions with Kayexalate (sodium polystyrene sulfonate) which include:
More about Kayexalate (sodium polystyrene sulfonate)
- Kayexalate consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: cation exchange resins
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.